cefpodoxime-proxetil and Chronic-Disease

The clinical usefulness of cefpodoxime proxetil (CPDX-PR) was investigated in the treatment of pneumonia and chronic airway infections occurring in patients first visiting our outpatient clinic or those being treated at the outpatient clinic. CPDX-PR was orally administered twice a day after meals at a dose of 100-200 mg for acute respiratory tract infections and at a dose of 200 mg for chronic respiratory tract infections. Excellent, good, fair, and poor responses were observed in 20, 33, 10, and 3 of 66 patients (4 with acute bronchitis, 27 with pneumonia, and 35 with acute exacerbation of chronic airway infection), respectively, demonstrating an 80.3% efficacy rate (53/66). Causative organisms, including Streptococcus pneumoniae, were all eradicated from the patients whose causative organisms were examined over time, although 2 of the patients were superinfected with Pseudomonas aeruginosa. There were no serious adverse reactions or abnormal changes in laboratory test results. It was concluded that CPDX-PR could be used as a first-choice drug for the treatment of respiratory tract infections at an outpatient clinic, and that this drug should acquire greater importance in particular consideration of recent increases in infections with S. pneumoniae.

Topics: Adult; Aged; Aged, 80 and over; Cefpodoxime Proxetil; Ceftizoxime; Chronic Disease; Female; Humans; Male; Middle Aged; Pneumococcal Infections; Pneumonia; Respiratory Tract Infections

This European, multicentre trial evaluated the efficacy and tolerance of cefpodoxime proxetil in comparison with co-amoxiclav (amoxycillin plus clavulanic acid) in the treatment of acute exacerbations of chronic bronchitis. The study design was double-blind and double-placebo controlled. Doses of either 200 mg bd of cefpodoxime proxetil or 500 mg/125 mg tds amoxycillin plus clavulanic acid were given orally for 9.6 +/- 1.8 days. Two hundred and fifty-one patients were enrolled in 27 centres in West Germany, France, and Italy. The overall clinical efficacy was 97.2% in the cefpodoxime proxetil group compared with 94.7% in the co-amoxiclav group. Fifty-eight adverse events, mainly gastrointestinal, occurred in 42 patients with no significant difference between the groups. A significant difference in the number of resistant pathogens on pre-treatment culture to the advantage of cefpodoxime was noted. In our experience, both drugs were of similar value in the treatment of respiratory tract infections. Thus, cefpodoxime proxetil should be an effective antibiotic for the treatment of acute exacerbations of chronic bronchitis.

Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Cefpodoxime Proxetil; Ceftizoxime; Chronic Disease; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prodrugs

Topics: Adult; Aged; Aged, 80 and over; Cefaclor; Cefpodoxime Proxetil; Ceftizoxime; Cephalexin; Cephalosporins; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Middle Aged; Multicenter Studies as Topic; Respiratory Tract Infections

Topics: Bronchitis; Cefpodoxime Proxetil; Ceftizoxime; Chronic Disease; Humans; Pneumonia, Bacterial; Prodrugs; Risk Factors